LeMaitre Vascular (NASDAQ:LMAT) Releases Q3 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its third quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.42 to $0.46 for the period, compared to the consensus estimate of $0.42. The company issued revenue guidance of $52.7 million to $54.7 million, compared to the consensus revenue estimate of $52.33 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.820-1.910 EPS.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Barrington Research upped their price objective on LeMaitre Vascular from $79.00 to $92.00 and gave the company an outperform rating in a report on Friday. Roth Mkm reiterated a buy rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday. They set a buy rating and a $105.00 price target on the stock. StockNews.com cut LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday. Finally, JMP Securities upped their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $86.50.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded down $1.24 during trading hours on Friday, reaching $85.01. 348,354 shares of the company were exchanged, compared to its average volume of 157,693. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $91.76. The stock’s fifty day moving average is $82.69 and its 200 day moving average is $71.79. The firm has a market cap of $1.91 billion, a PE ratio of 56.30, a PEG ratio of 2.63 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter in the prior year, the company earned $0.37 earnings per share. The company’s revenue was up 11.4% on a year-over-year basis. Research analysts expect that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at $156,558,338.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold 127,437 shares of company stock valued at $10,076,242 over the last quarter. 10.79% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.